The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

COPD, or chronic obstructive pulmonary disease, affects more than 30 million Americans, yet many have never heard of it. COPD ...

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

Digital inhalers may help predict impending acute exacerbations of chronic obstructive pulmonary disease (COPD), according to ...

Many individuals with chronic obstructive pulmonary disease describe exacerbations in personal, varied terms, revealing a ...

Upstream Bio has dosed the first subject in the Phase II trial of verekitug in individuals with chronic obstructive pulmonary disease (COPD).

Researchers have found in two longitudinal cohorts that Incorporating chest CT imaging and respiratory symptoms into the ...

Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...